• Lion share of infrastructure investments taken in 2013-2015

• Initial problems in production and product design now solved

• Actions set in motion to reduce costs:

– Reducing staff and reorganising– Prioritising existing product ranges

• Market remains attractive / growing demand for safety products

• Confirmed strong interest from our distribution partners

• Rights issue to finance sales efforts in Europe and expected growth

• Technical challenges caused delays and affected distributors and end-user confidence

– Re-design of the Vigclip® led to a delay in market acceptance of the CLiP® product lines, and temporary loss of distributor and end-user confidence

– The SWiNG product lines entered the market later than planned due to manufacturing problems, causing loss of market position as competitive products with different features have penetrated the market

• It has taken longer than expected and costed more

– Unexpected delays due to (A) initial production issues (8 months), (B) design improvement of the Vigclip® (6 months) and (C) authority approval processes (4 months)

– Additional costs due to (A) rework of production tools and loss of production time, (B) replacement of affected CLiP® Winged products and (C) additional tests required for CE approvals

Company updateOur learnings… Present position

Significant loss of sales and income

Sales is expected to pick-up during 2016

2

Vigmed’s 3 brands and 5 product lines

CLiP® Ported CLiP® Winged SWiTCH

Infusion Artery Injection

SWiNG

Currently in marketCurrently in

pre-launchCurrently under

market evaluation

CLiP® Neo

CLiP® Ported is an automatic passive safety catheter with no action required by user and with precise tip configuration

CLiP® Winged is designed to give users the flexibility of grip choices, even on a non-ported safety I.V. catheter – the wings keep the catheter stationary, stable and secure under dressing or other fixation

CLiP® Neo is a winged safety catheter, specifically designed for small veins found in the neonatal, paediatric or elderly patient groups

SWiTCH arterial catheter is a unique needle protected safety product which also offers blood control

SWiNG is the first safety cover for hypodermic needles that once activated, automatically prevents needlestick injuries both during and after injection

3

Distribution

Additional contracts are currently under negotiation

Sweden

Norway

France

SpainPortugal

Greece

Italy

Denmark

CODAN

CODAN

CODAN

Device TechnologiesAustralia

MedicináliaCormédica

CODAN

Izasa Hospital

Medi.CaMedivalNannini

Mavrogenis

Germany

Hospithera

Austria

CODANBelgium

Switzerland

Mediq

Icepharma

VygonMedica

Vestek AB

Australia

New Zealand

Distribution network with vast geographical reach Comments from distributors

IcelandWe expect to be able to enter the French market with full force

now that we have a complete range of products. We are currently participating in several tenders and new pre-tender tests are being evaluated on the upgraded products. SWiTCH complements our product offering very well and we have high

expectations on this product range.- CODAN France

We think SWiTCH can be the door-opener for the Swiss market with its unique, feasible and ingenious features.

Mediq Suisse - Switzerland

After a period of trials we are proud to announce that we have successfully converted several units to using Vigmed’s safety products. The coming months will be spent building on this success and our aim is to have Vigmed Catheters used in every state by the end of the year.

- Device Technologies, Australia

4

Market potential and target in Europe - 2018

Product group Market size Current salesSales target &going forward

CLiP® 385m units 6-7% PIVC market size and market share Europe

SWiNG 6,000m units < 1,5%Hypodermic needles market size and share Europe

SWiTCH 6m units 30-32%Direct artery puncture market size and share Europe

Product groupEuropean

market sizeTarget market share Comments

5

• Only CLiP® , SWiTCH and SWiNG included in financial targets

• Only European markets (plus minor CE markets) included in financial targets

• Upside potential from additional product launches, entry into new geographies and license agreements

6

Financial targets 2018

• Sales 150 MSEK

• Full year cash-flow and EBIT positive if sales target is met